Research on Effects of Drugs on Body Composition and Function With Imaging in Diabetes

Launched by KRISTIN CLEMENS ·

Keywords

ClinConnect Summary

This is a small, forward-looking study of about 20 adults with type 2 diabetes who have recently started a GLP-1 receptor drug (semaglutide) or a GLP-1/GLP-1RA-GIP combo (tirzepatide). Researchers want to learn how these medicines affect muscle and bone health, including blood flow and how the muscles use sugar. They’ll use advanced body scans (PET/CT) and simple tests of function to look at muscle mass, muscle quality, blood flow, and how strong or mobile people are. Key goals are to describe changes over 3, 6, and 12 months and to see if any early changes could signal risk to muscle or bone.

People who may be eligible are adults 18 and older with type 2 diabetes who have recently started semaglutide or tirzepatide under a clinician’s care. You cannot join if you’re pregnant or breastfeeding, unable to do the required tests, have a reason PET/CT can’t be done, had a recent weight change of more than 5 kg in the 90 days before starting treatment, or are planning bariatric surgery within the next year. The study runs about a year with visits at baseline, 3, 6, and 12 months, is open-label and not randomized (no control group), and is being conducted in Canada at Western University. Results aren’t available yet—the trial is planned to begin around October 2025 and finish by the end of 2027. The aim is to help doctors predict who might be at risk for muscle or bone problems and to guide ways to protect muscle and bone while these medicines are used.

Gender

ALL

Eligibility criteria